Satellos Bioscience reported six-month interim TRAILHEAD data for SAT-3247 in adults with Duchenne Muscular Dystrophy (DMD). Results demonstrated reduced muscle fat fraction, increased effort, stable strength, lower creatine kinase (CK) levels, and a favorable safety profile. The company operates in the biotechnology industry and develops therapies for muscle-wasting diseases.
